Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [172]
News [237]
Articles [13]
Editorials [0]
Conferences [83]
elearning [2]
PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning
Dr Shernan Holtan - University of Minnesota, Minneapolis, USA
PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning ( Dr Shernan Holtan - University of Minnesota, Minneapolis, USA )
15 Dec 2022
An analysis of the worldwide utilisation of haematopoietic stem cell...
Dr Molly Tokaz - Fred Hutchinson Cancer Center, Seattle, USA
An analysis of the worldwide utilisation of haematopoietic stem cell transplantation for acute myeloid leukaemia ( Dr Molly Tokaz - Fred Hutchinson Cancer Center, Seattle, USA )
14 Dec 2022
ESMO 2022: Highlights, commentary and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2022: Highlights, commentary and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
12 Sep 2022
OncoAlert and ecancer weekly round up for August 15th - 21st, 2022
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly round up for August 15th - 21st, 2022 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
22 Aug 2022
Working to improve global cancer care access in low middle-income countries
Dr Julie Gralow, Prof Eduardo Cazap
Working to improve global cancer care access in low middle-income countries ( Dr Julie Gralow, Prof Eduardo Cazap )
25 Jul 2022
EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for...
Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA
EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )
14 Jun 2022
Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy...
Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany
Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients ( Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany )
13 Jun 2022
COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity...
Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA
COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma ( Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA )
5 Jun 2022
Safety follow-up of the randomized, phase 3 study DESTINY-Breast03
Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA
Safety follow-up of the randomized, phase 3 study DESTINY-Breast03 ( Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA )
5 Jun 2022
High-dose ifosfamide standard of care for recurrent and primary refractory...
Dr Martin McCabe - University of Manchester, Manchester, England
High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma ( Dr Martin McCabe - University of Manchester, Manchester, England )
5 Jun 2022
Lung cancer in India
Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India
Lung cancer in India ( Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India )
3 Feb 2022
OncoAlert Colloquium Day 6: Gynaecological oncology, IGCS and ESO
Dr Don Dizon, Dr Allison Betof Warner, Dr Giancarlo Pruneri, Dr Pierfrancesco...
OncoAlert Colloquium Day 6: Gynaecological oncology, IGCS and ESO ( Dr Don Dizon, Dr Allison Betof Warner, Dr Giancarlo Pruneri, Dr Pierfrancesco Franco & Dr Kathleen Schemeler )
19 Jan 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation